Published in Cancer Biol Ther on February 01, 2004
The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell (2013) 2.37
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med (2008) 2.10
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene (2010) 1.45
Notch signaling is necessary for epithelial growth arrest by TGF-beta. J Cell Biol (2007) 1.36
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
P21waf1/cip1/sdi1 as a central regulator of inducible smooth muscle actin expression and differentiation of cardiac fibroblasts to myofibroblasts. Mol Biol Cell (2007) 1.13
A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol Cell Biol (2013) 1.10
The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res (2012) 1.07
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
P21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biol Ther (2007) 0.95
Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene (2010) 0.94
p21(WAF1/CIP1) at the switch between the anti-oncogenic and oncogenic faces of TGFbeta. Cancer Biol Ther (2004) 0.88
Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype. J Cell Biochem (2012) 0.88
PUMA Cooperates with p21 to Regulate Mammary Epithelial Morphogenesis and Epithelial-To-Mesenchymal Transition. PLoS One (2013) 0.84
MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A (2014) 0.82
Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications. Cancer Biol Ther (2012) 0.81
Expression of Smad4, TGF-βRII, and p21(waf1) in esophageal squamous cell carcinoma tissue. Oncol Lett (2015) 0.75
Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. Oncotarget (2016) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
International network of cancer genome projects. Nature (2010) 20.35
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res (2006) 2.66
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol (2009) 2.34
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nat Biotechnol (2006) 2.31
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res (2004) 2.29
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell (2008) 2.15
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med (2008) 2.10
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol (2005) 2.03
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00